Aquestive Therapeutics Files 8-K
Ticker: AQST · Form: 8-K · Filed: Oct 1, 2025 · CIK: 1398733
| Field | Detail |
|---|---|
| Company | Aquestive Therapeutics, Inc. (AQST) |
| Form Type | 8-K |
| Filed Date | Oct 1, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, financials, corporate-filing
Related Tickers: AQST
TL;DR
AQST filed an 8-K on Oct 1st - standard disclosure, check financials.
AI Summary
Aquestive Therapeutics, Inc. filed an 8-K on October 1, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as MonoSol Rx, Inc., is based in Warren, NJ, and operates in the Pharmaceutical Preparations industry.
Why It Matters
This filing indicates routine corporate reporting, including financial updates and exhibits, which are important for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This is a standard 8-K filing for corporate disclosures and exhibits, not indicating any specific material events or risks.
Key Players & Entities
- Aquestive Therapeutics, Inc. (company) — Registrant
- MonoSol Rx, Inc. (company) — Former company name
- October 1, 2025 (date) — Date of report
- 30 Technology Drive Warren, NJ 07059 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Aquestive Therapeutics, Inc.?
The primary purpose is to report a Regulation FD Disclosure and to file Financial Statements and Exhibits as of October 1, 2025.
When was Aquestive Therapeutics, Inc. previously known by another name?
Aquestive Therapeutics, Inc. was formerly known as MonoSol Rx, Inc., with a date of name change on May 7, 2007.
What is the industry classification for Aquestive Therapeutics, Inc.?
The company is classified under Pharmaceutical Preparations [2834].
Where are Aquestive Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 30 Technology Drive, Warren, NJ 07059.
What is the fiscal year end for Aquestive Therapeutics, Inc.?
The fiscal year end for Aquestive Therapeutics, Inc. is December 31.
Filing Stats: 589 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-10-01 08:41:31
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share AQST Nasdaq Global Market I
Filing Documents
- aqst-20251001.htm (8-K) — 27KB
- corporatepresentationoct.htm (EX-99.1) — 29KB
- corporatepresentationoct001.jpg (GRAPHIC) — 98KB
- corporatepresentationoct002.jpg (GRAPHIC) — 329KB
- corporatepresentationoct003.jpg (GRAPHIC) — 103KB
- corporatepresentationoct004.jpg (GRAPHIC) — 116KB
- corporatepresentationoct005.jpg (GRAPHIC) — 123KB
- corporatepresentationoct006.jpg (GRAPHIC) — 106KB
- corporatepresentationoct007.jpg (GRAPHIC) — 109KB
- corporatepresentationoct008.jpg (GRAPHIC) — 102KB
- corporatepresentationoct009.jpg (GRAPHIC) — 83KB
- corporatepresentationoct010.jpg (GRAPHIC) — 51KB
- corporatepresentationoct011.jpg (GRAPHIC) — 115KB
- corporatepresentationoct012.jpg (GRAPHIC) — 95KB
- corporatepresentationoct013.jpg (GRAPHIC) — 88KB
- corporatepresentationoct014.jpg (GRAPHIC) — 130KB
- corporatepresentationoct015.jpg (GRAPHIC) — 118KB
- corporatepresentationoct016.jpg (GRAPHIC) — 104KB
- corporatepresentationoct017.jpg (GRAPHIC) — 114KB
- corporatepresentationoct018.jpg (GRAPHIC) — 75KB
- corporatepresentationoct019.jpg (GRAPHIC) — 38KB
- corporatepresentationoct020.jpg (GRAPHIC) — 115KB
- corporatepresentationoct021.jpg (GRAPHIC) — 136KB
- corporatepresentationoct022.jpg (GRAPHIC) — 129KB
- corporatepresentationoct023.jpg (GRAPHIC) — 67KB
- corporatepresentationoct024.jpg (GRAPHIC) — 36KB
- 0001398733-25-000020.txt ( ) — 3738KB
- aqst-20251001.xsd (EX-101.SCH) — 2KB
- aqst-20251001_lab.xml (EX-101.LAB) — 21KB
- aqst-20251001_pre.xml (EX-101.PRE) — 12KB
- aqst-20251001_htm.xml (XML) — 3KB
01
Item 7.01 Regulation FD Disclosure. Aquestive Therapeutics, Inc. (the "Company") is furnishing this Current Report on Form 8-K in connection with the disclosure of information, in the form of an investor presentation, to be given at meetings with institutional investors, analysts and others. This information may be amended or updated at any time and from time to time through another Current Report on Form 8-K, a later Company filing or other means. A copy of the Company's investor presentation is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. The investor presentation is available on the Events and Presentations Page of the Investors section of the Company's website located at www.aquestive.com, although the Company reserves the right to discontinue that availability at any time. The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of, or otherwise subject to the liabilities of, Section 18 of the Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Aquestive Therapeutics, Inc. Corporate Presentation dated October 2025 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 1, 2025 Aquestive Therapeutics, Inc. By: /s/ A. Ernest Toth, Jr Name: A. Ernest Toth, Jr. Title: Chief Financial Officer